ROIVANT SCIENCES LTD. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
ROIVANT SCIENCES LTD. (ROIV) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $7.10 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2024-08-09
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $7.10M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.50M.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $4.70M.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $7.10M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2024-06-30 | $7.10M 10-Q · filed 2024-08-09 |
| 2023-12-31 | $2.50M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $4.70M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $7.10M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $6.70M 10-Q · filed 2022-08-15 |
| 2022-12-31 | $2.30M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $4.30M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |